论文部分内容阅读
新型胃动力药—吗丁啉,主药为多潘立酮(Domperidone)是一种外周多巴胺受体阻滞剂.不通过血脑屏障,对脑内多巴胺受体无抑制作用。因此,本品无锥体外系等神经精神副作用。药理研究表明,静脉注射本品后,对脑电图、心电图及呼吸均无影响。本品犬口服LD50为>160mg/kg,急性毒性和长期毒性试验,经心、肺、肝、肾病理检查,均未见异常。本品口服及直肠给药均可,吸收迅速,以胃肠局部药物浓度最高,血浆次之,脑内几乎没有。口服后15—30min,达峰值血药浓度,直肠给药为1 h.血浆
The new gastric motility drug - domperidone, the main drug Domperidone (Domperidone) is a peripheral dopamine receptor blocker, does not pass the blood-brain barrier, no inhibitory effect on the brain dopamine receptors. Therefore, this product is no extrapyramidal neuropsychiatric side effects. Pharmacological studies have shown that intravenous injection of this product, the EEG, ECG and breathing did not affect. The dog oral LD50> 160mg / kg, acute toxicity and long-term toxicity test, cardiac, lung, liver and kidney pathology examination, were no abnormalities. This product can be administered orally and rectally, quickly absorbed to the highest concentration of gastrointestinal local medicine, followed by plasma, almost no brain. After oral administration of 15-30min, peak plasma concentration, rectal administration of 1 h. Plasma